{"id":"daratumumab-hyaluronidase","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Muscle spasms"},{"rate":"10-30%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1743007","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Daratumumab is a monoclonal antibody that binds to CD38, a protein found on the surface of multiple myeloma cells. Hyaluronidase is an enzyme that helps to break down hyaluronic acid, a component of the extracellular matrix, allowing the monoclonal antibody to penetrate deeper into the tumor tissue.","oneSentence":"Daratumumab-hyaluronidase is a monoclonal antibody-drug conjugate that targets CD38 on cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:13.657Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT07485647","phase":"PHASE2","title":"Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing","status":"NOT_YET_RECRUITING","sponsor":"Eden Biltibo","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05907759","phase":"PHASE2","title":"Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-10","conditions":"Lymphoma, Primary Effusion","enrollment":28},{"nctId":"NCT03301220","phase":"PHASE3","title":"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-07","conditions":"Smoldering Multiple Myeloma","enrollment":390},{"nctId":"NCT06142396","phase":"EARLY_PHASE1","title":"Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-11-01","conditions":"Multiple Myeloma, Renal Failure","enrollment":30},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":"Non-small Cell Lung Cancer With STK11/LKB1 Mutation","enrollment":8},{"nctId":"NCT06192979","phase":"NA","title":"Optimize First-line Treatment for AL Amyloidosis With t (11; 14)","status":"RECRUITING","sponsor":"Jin Lu, MD","startDate":"2024-01-05","conditions":"Amyloidosis; Systemic, AL Amyloidosis","enrollment":41},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT05289687","phase":"PHASE2","title":"Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL","status":"RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2023-05-25","conditions":"T-cell Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":21},{"nctId":"NCT07285239","phase":"PHASE3","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT05511428","phase":"PHASE4","title":"Home Based Daratumumab Administration for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-11-08","conditions":"Plasma Cell Myeloma","enrollment":20},{"nctId":"NCT07110844","phase":"PHASE2","title":"Teclistamab-Daratumumab in AL Amyloidosis","status":"RECRUITING","sponsor":"Suzanne Lentzsch, MD","startDate":"2025-11-07","conditions":"Amyloid Light-chain Amyloidosis","enrollment":25},{"nctId":"NCT05139225","phase":"PHASE1","title":"A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-28","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT05300451","phase":"PHASE2","title":"Daratumumab in HLA Desensitization Prior to Transplantation","status":"ENROLLING_BY_INVITATION","sponsor":"Barry A. Boilson","startDate":"2022-03-31","conditions":"Cardiac Transplant","enrollment":10},{"nctId":"NCT03590652","phase":"PHASE2","title":"Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2018-10-17","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":23},{"nctId":"NCT06046287","phase":"PHASE2","title":"Daratumumab for Polyneuropathy Associated With MGUS","status":"WITHDRAWN","sponsor":"Georgetown University","startDate":"2025-09-26","conditions":"Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance","enrollment":""},{"nctId":"NCT06398457","phase":"EARLY_PHASE1","title":"Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-09-19","conditions":"Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML)","enrollment":8},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":"AL Amyloidosis","enrollment":338},{"nctId":"NCT07085728","phase":"PHASE2","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-08-11","conditions":"Myeloma Multiple","enrollment":74},{"nctId":"NCT05561387","phase":"PHASE3","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-10-12","conditions":"Plasma Cell Myeloma","enrollment":510},{"nctId":"NCT02519452","phase":"PHASE1","title":"A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-22","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT03277105","phase":"PHASE3","title":"A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-27","conditions":"Multiple Myeloma","enrollment":522},{"nctId":"NCT04131309","phase":"PHASE2","title":"A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"Stichting European Myeloma Network","startDate":"2019-09-23","conditions":"Light Chain (AL) Amyloidosis, Stage 3B","enrollment":40},{"nctId":"NCT06622005","phase":"PHASE1","title":"SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2025-04-10","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":15},{"nctId":"NCT05004259","phase":"PHASE1","title":"The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2022-03-21","conditions":"Hemolytic Anemia","enrollment":2},{"nctId":"NCT03320707","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-16","conditions":"Healthy","enrollment":66},{"nctId":"NCT04782687","phase":"PHASE2","title":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"US Oncology Research","startDate":"2021-09-10","conditions":"Multiple Myeloma, Myeloma Multiple, Kahler Disease","enrollment":73},{"nctId":"NCT06107738","phase":"PHASE2","title":"Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma","status":"RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2023-12-21","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04714372","phase":"PHASE1","title":"FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2021-11-03","conditions":"Acute Myeloid Leukemia, Myeloid Leukemia, Monocytic Leukemia","enrollment":9},{"nctId":"NCT04776018","phase":"PHASE1, PHASE2","title":"A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-04-20","conditions":"Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":27},{"nctId":"NCT06455748","phase":"NA","title":"Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study","status":"RECRUITING","sponsor":"Yongyong MA","startDate":"2024-03-01","conditions":"Amyloid Light-chain Amyloidosis","enrollment":20},{"nctId":"NCT04956302","phase":"PHASE1","title":"Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Abdullah Khan","startDate":"2021-09-27","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":1},{"nctId":"NCT06376214","phase":"NA","title":"Daratumumab for Patients With Light Chain Amyloidosis","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2023-01-01","conditions":"Light Chain (AL) Amyloidosis","enrollment":100},{"nctId":"NCT04121260","phase":"PHASE1","title":"A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-25","conditions":"Multiple Myeloma","enrollment":21},{"nctId":"NCT05205252","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.","status":"WITHDRAWN","sponsor":"Epizyme, Inc.","startDate":"2021-12-22","conditions":"Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy","enrollment":""},{"nctId":"NCT03242889","phase":"PHASE1","title":"A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2017-08-10","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT05408026","phase":"PHASE1, PHASE2","title":"Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM","status":"WITHDRAWN","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2022-10-01","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT04150692","phase":"PHASE2","title":"Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2021-01-08","conditions":"Multiple Myeloma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Darzalex FASPRO®"],"phase":"phase_2","status":"active","brandName":"Daratumumab-hyaluronidase","genericName":"Daratumumab-hyaluronidase","companyName":"Eastern Cooperative Oncology Group","companyId":"eastern-cooperative-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daratumumab-hyaluronidase is a monoclonal antibody-drug conjugate that targets CD38 on cancer cells. Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}